Literature DB >> 29439972

Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam.

Michiyoshi Nukaga1, Krisztina M Papp-Wallace2,3,4, Tyuji Hoshino5, Scott T Lefurgy6, Christopher R Bethel7, Melissa D Barnes7,3, Elise T Zeiser7, J Kristie Johnson8, Robert A Bonomo2,3,9,10.   

Abstract

Ceftazidime-avibactam is a "second-generation" β-lactam-β-lactamase inhibitor combination that is effective against Enterobacteriaceae expressing class A extended-spectrum β-lactamases, class A carbapenemases, and/or class C cephalosporinases. Knowledge of the interactions of avibactam, a diazabicyclooctane with different β-lactamases, is required to anticipate future resistance threats. FOX family β-lactamases possess unique hydrolytic properties with a broadened substrate profile to include cephamycins, partly as a result of an isoleucine at position 346, instead of the conserved asparagine found in most AmpCs. Interestingly, a single amino acid substitution at N346 in the Citrobacter AmpC is implicated in resistance to the aztreonam-avibactam combination. In order to understand how diverse active-site topologies affect avibactam inhibition, we tested a panel of clinical Enterobacteriaceae isolates producing blaFOX using ceftazidime-avibactam, determined the biochemical parameters for inhibition using the FOX-4 variant, and probed the atomic structure of avibactam with FOX-4. Avibactam restored susceptibility to ceftazidime for most isolates producing blaFOX; two isolates, one expressing blaFOX-4 and the other producing blaFOX-5, displayed an MIC of 16 μg/ml for the combination. FOX-4 possessed a k2/K value of 1,800 ± 100 M-1 · s-1 and an off rate (koff) of 0.0013 ± 0.0003 s-1 Mass spectrometry showed that the FOX-4-avibactam complex did not undergo chemical modification for 24 h. Analysis of the crystal structure of FOX-4 with avibactam at a 1.5-Å resolution revealed a unique characteristic of this AmpC β-lactamase. Unlike in the Pseudomonas-derived cephalosporinase 1 (PDC-1)-avibactam crystal structure, interactions (e.g., hydrogen bonding) between avibactam and position I346 in FOX-4 are not evident. Furthermore, another residue is not observed to be close enough to compensate for the loss of these critical hydrogen-bonding interactions. This observation supports findings from the inhibition analysis of FOX-4; FOX-4 possessed the highest Kd (dissociation constant) value (1,600 nM) for avibactam compared to other AmpCs (7 to 660 nM). Medicinal chemists must consider the properties of extended-spectrum AmpCs, such as the FOX β-lactamases, for the design of future diazabicyclooctanes.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  avibactam; beta-lactam; beta-lactamase; cephamycinase

Mesh:

Substances:

Year:  2018        PMID: 29439972      PMCID: PMC5923096          DOI: 10.1128/AAC.02371-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Authors:  Thérèse Stachyra; Marie-Claude Péchereau; Jean-Michel Bruneau; Monique Claudon; Jean-Marie Frère; Christine Miossec; Kenneth Coleman; Michael T Black
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  Kinetics of the interaction between avibactam and the CHE-1 class C β-lactamase.

Authors:  Adriana Fernea; Moreno Galleni; Jean-Marie Frère
Journal:  J Antimicrob Chemother       Date:  2014-10-31       Impact factor: 5.790

4.  Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain.

Authors:  E Miró; J Agüero; M N Larrosa; A Fernández; M C Conejo; G Bou; J J González-López; N Lara; L Martínez-Martínez; A Oliver; B Aracil; J Oteo; A Pascual; J Rodríguez-Baño; L Zamorano; F Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-07       Impact factor: 3.267

5.  Characterization of FOX-3, an AmpC-type plasmid-mediated beta-lactamase from an Italian isolate of Klebsiella oxytoca.

Authors:  A Marchese; G Arlet; G C Schito; P H Lagrange; A Philippon
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster.

Authors:  Thierry Fosse; Chantal Giraud-Morin; Isabelle Madinier; Roger Labia
Journal:  FEMS Microbiol Lett       Date:  2003-05-16       Impact factor: 2.742

8.  Detection of plasmid-mediated AmpC β-lactamase in Escherichia coli and Klebsiella pneumoniae.

Authors:  N O Yilmaz; N Agus; E Bozcal; O Oner; A Uzel
Journal:  Indian J Med Microbiol       Date:  2013 Jan-Mar       Impact factor: 0.985

9.  AmpC-BETA Lactamases among Enterobacteriaceae Isolated at a Tertiary Hospital, South Western Uganda.

Authors:  Martha Nakaye; Freddie Bwanga; Herbert Itabangi; Iramiot J Stanley; Mwambi Bashir; Joel Bazira
Journal:  Br Biotechnol J       Date:  2014-09

10.  Analysis Tool Web Services from the EMBL-EBI.

Authors:  Hamish McWilliam; Weizhong Li; Mahmut Uludag; Silvano Squizzato; Young Mi Park; Nicola Buso; Andrew Peter Cowley; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2013-05-13       Impact factor: 16.971

View more
  7 in total

1.  Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308.

Authors:  Pablo A Fraile-Ribot; Cristóbal Del Rosario-Quintana; Carla López-Causapé; María A Gomis-Font; Mar Ojeda-Vargas; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Mechanism of proton transfer in class A β-lactamase catalysis and inhibition by avibactam.

Authors:  Orville A Pemberton; Radwan E Noor; Vasantha Kumar M V; Ruslan Sanishvili; M Trent Kemp; Fiona L Kearns; H Lee Woodcock; Ioannis Gelis; Yu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 3.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

4.  Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion.

Authors:  Akito Kawai; Christi L McElheny; Alina Iovleva; Ellen G Kline; Nicolas Sluis-Cremer; Ryan K Shields; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

5.  Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases.

Authors:  Jean-Marie Frère; Pierre Bogaerts; Te-Din Huang; Patrick Stefanic; Joël Moray; Fabrice Bouillenne; Alain Brans
Journal:  Biomolecules       Date:  2020-03-23

Review 6.  Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.

Authors:  Giacomo Luci; Francesca Mattioli; Marco Falcone; Antonello Di Paolo
Journal:  Antibiotics (Basel)       Date:  2021-06-24

7.  Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.

Authors:  Pauline A Lang; Thomas M Leissing; Malcolm G P Page; Christopher J Schofield; Jürgen Brem
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.